A recent study illustrated that low-dose apatinib with anti-PD-L1 antibody optimized tumor microenvironment by alleviating hypoxia, promoting the infiltration of CD8 (+) T cells, reducing recruitment of tumor-associated macrophages in lung cancer [15]. This evidence concerns the gene CD8A and lung cancer.